Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2016 1
2020 2
2021 4
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Nakamura A, Tanaka H, Saito R, Suzuki A, Harada T, Inoue S, Yamada T, Nakagawa T, Jingu D, Sugawara S. Nakamura A, et al. Among authors: jingu d. Oncologist. 2020 Oct;25(10):e1451-e1456. doi: 10.1634/theoncologist.2020-0545. Epub 2020 Jul 7. Oncologist. 2020. PMID: 32559335 Free PMC article. Clinical Trial.
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
Minegishi Y, Akagami T, Arai M, Saito R, Arai D, Murase K, Miura K, Watanabe S, Sakashita H, Miyabayashi T, Honda R, Jingu D, Hotta T, Isobe K, Nakazawa K, Ito K, Takamura K, Inomata M, Harada T, Sakakibara R, Nakagawa T, Shibuya H, Takenaka K, Kobayashi K, Seike M. Minegishi Y, et al. Among authors: jingu d. Lung Cancer. 2022 Oct;172:1-8. doi: 10.1016/j.lungcan.2022.07.009. Epub 2022 Jul 26. Lung Cancer. 2022. PMID: 35952438 Review.
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Oizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: jingu d. Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8. Int J Clin Oncol. 2022. PMID: 35257278 Free PMC article. No abstract available.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: jingu d. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
13 results